Drug Approval | November 15, 2025
Zydus receives final approval from USFDA for Leuprolide Acetate injection
Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer
Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer
Diroximel fumarate delayed-release capsules, 231 mg, are indicated for the treatment of relapsing forms of multiple sclerosis
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
Budesonide is indicated for mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in adults and children 8 years of age and olde
Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ
Prucalopride is prescribed for chronic idiopathic constipation
With this addition, the company’s total Installed MCC Capacity will rise to 30,000 MTPA
This is the group’s first NoC approval in Canada
Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad
Celecoxib is a nonsteroidal anti-inflammatory drug
Subscribe To Our Newsletter & Stay Updated
